Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-24

Clinical Trial Update: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating subcutaneous icatibant for acute attacks of hereditary angioedema has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ICATIBANT (icatibant)

Snippet

Sponsor: Shire | Conditions: Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2013-12-24